title: Value of a gene signature assay in patients with early breast cancer and intermediate risk: a single institution retrospective study.
abstract: Purpose In daily clinical practice, the indication for adjuvant chemotherapy (CT) is relatively easy to make in patients with early hormone-receptor-positive (HR+) breast cancer with either very poor or very good clinicopathological prognostic variables. However, this decision is much more difficult in patients with intermediate clinicopathological prognostic variables. Here, we evaluate the value of a gene-expression profile identified by the Prosigna gene signature assay in guiding treatment decision-making in patients with these intermediate features. Methods A consecutive cohort of 577 HR + breast cancer patients surgically treated in a single institution between January 2012 and December 2012 was evaluated. From this population, pre- and post-menopausal patients with intermediate prognosis clinicopathological variables were identified and indication of adjuvant CT in these patients was recorded. The gene signature assay was performed retrospectively in this intermediate risk group. Descriptive statistics are presented. Results Among 96 intermediate-risk patients, 64 postmenopausal patients underwent gene signature testing. Subtype distribution was as follows: Luminal A (N = 33; 51.6%), Luminal B (N = 31; 48.4%). Risk of recurrence (ROR) distribution was as follows: ROR-low (n = 16; 25%); ROR-intermediate (N = 26; 40.6%); and ROR-high (N = 22; 34.4%). CT was subsequently administered in 18.7%, 53.8% and 59.0% of the ROR-low, ROR-intermediate and ROR-high groups, respectively. With the use of the gene signature assay, 59.4% of the intermediate cases were re-classified to either ROR-low or ROR-high risk categories. In the ROR-intermediate group, 11/26 patients (42.3%) had Luminal A and 15/26 (57.7%) had Luminal B. Due to follow-up time constraints, no patient outcome results were evaluated. Conclusion The gene signature assay provides clinically useful information and improved treatment decision-making in patients with intermediate risk based on clinicopathological factors. Determining the patient's intrinsic subtype and ROR can aid clinicians in deciding whether CT should be indicated.
authors.affiliation: a Lille University , Centre Oscar Lambret, Breast Cancer Department , Lille , France ;
authors.forename: Jacques
authors.initials: J
authors.lastname: Bonneterre
authors.affiliation: b Vall D'Hebron Institute of Oncology , Barcelona , Spain .
authors.forename: Aleix
authors.initials: A
authors.lastname: Prat
authors.affiliation: b Vall D'Hebron Institute of Oncology , Barcelona , Spain .
authors.forename: Patricia
authors.initials: P
authors.lastname: Galván
authors.affiliation: c Nanostring Technologies Inc. , Seattle , WA , USA.
authors.forename: Pascale
authors.initials: P
authors.lastname: Morel
authors.affiliation: a Lille University , Centre Oscar Lambret, Breast Cancer Department , Lille , France ;
authors.forename: Sylvia
authors.initials: S
authors.lastname: Giard
mesh_terms: D001943:Breast Neoplasms / Q000188:drug therapy* / Q000235:genetics; D017024:Chemotherapy, Adjuvant / Q000379:methods*; D005260:Female; D006801:Humans; D011379:Prognosis; D012189:Retrospective Studies; D012306:Risk
keywords: Adjuvant; Breast cancer; Genomic; Intrinsic subtypes; PAM50